Skip to content

The Impact of COVID-19 on Short-Term Prognosis of ST-Segment Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention in Wuhan China: a Single-Center Retrospective Study

The Impact of COVID-19 on Short-Term Prognosis of ST-Segment Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention in Wuhan China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042315
Enrollment
Unknown
Registered
2021-01-18
Start date
2020-01-22
Completion date
Unknown
Last updated
2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-Segment Elevation Myocardial Infarction

Interventions

COVID-19 group:N/A
non COVID-19 group:N/A

Sponsors

General Hospital of Central Theater Command of PLA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The patients enrolled were STEMI patients who were treated at the CPC of General Hospital of Central Theater Command of the People's Liberation Army during the outbreak period from January 22 to April 30 in 2020 and same time in 2019. Patients who meet the following conditions were selected: 1. ST-segment arch-like elevation in 2 or more leads or new left bundle branch block, cardiac troponin T level exceeding the 99th percentile of the upper limit of normal reference and persistent ischemic chest pain lasting ?20 minutes; 2. emergency medical treatment in our hospital, concurrent PPCI surgery (including percutaneous coronary balloon dilation, thrombus aspiration and stent implantation).

Exclusion criteria

Exclusion criteria: 1. Non-ST segment elevation acute coronary syndrome (NSTE-ACS); 2. Delays in treatment, symptom relief, ST segment fall, hemodynamics and ECG stability, missed the opportunity for emergency revascularization; 3. Infarct-related artery (IRA) recanalization or residual mild stenosis, or three-vessel diffuse disease requiring bypass.

Design outcomes

Primary

MeasureTime frame
Major adverse cardiovascular event;

Countries

China

Contacts

Public ContactLu Qing

General Hospital of Central Theater Command of PLA

luqingluoli@163.com+86 13638635700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026